Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the pathological Complete Response (pCR)
rate by treatment arm (according to Chevallier criteria).
The secondary objectives are:
- to assess in each treatment arm the clinical Response Rate (RR), the rate of breast
conservation, the Progression-Free Survival (PFS), the Overall Survival (OS), the safety
and tolerability profile, the pathological Complete Response rate (pCR) according to
NSABP and Sataloff criteria,
- to rank docetaxel and larotaxel alone in Her2 -ve patients, or combined with trastuzumab
in Her2 +ve patients, according to the pCR rate.